ASIM GUHA ROY: Open Payments
NPI 1083659528 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$790 in 14 payments from 10 companies in 2025. Trend: 2023 $1,035 · 2024 $938 · 2025 $790
Food & beverage: $790
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 3 | $300 |
| Amgen Inc. | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Inspire Medical Systems, Inc. | 1 | $53 |
| MicroTransponder, Inc. | 1 | $34 |
| Lilly USA, LLC | 1 | $26 |
| Corcept Therapeutics | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
Products named: Nayzilam, UPLIZNA, AUSTEDO XR, REXULTI, INSPIRE, Briviact, MOUNJARO, Korlym.
Industry payments across CA — which companies pay providers there.
